GlassScriptPhysician profile
Rajani Prabhakaran
NPI 1316073067
$2,074.95
in general payments reported to CMS, 2019-2025
22 companies · $294 in 2025
The $294 reported for 2025 was less than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $31.97 · 2022: $455 · 2023: $492 · 2024: $646 · 2025: $294.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,432.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,431.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $298.89 | 2019-2023 | Dexcom G6 Transmitter |
| Eton Pharmaceuticals, INC. | $291.73 | 2023-2024 | Alkindi |
| Kyowa Kirin, INC. | $265.41 | 2023-2025 | Crysvita |
| Ascendis Pharma Endocrinology INC | $247.88 | 2024 | |
| Tolmar, INC. | $155.36 | 2023-2024 | |
| Beta Bionics, INC. | $143.45 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Tandem Diabetes Care, INC. | $133.09 | 2022 | |
| Novo Nordisk INC | $105.73 | 2022-2025 | Norditropin |
| Abbvie INC. | $70.00 | 2019 | |
| Amphastar Pharmaceuticals, INC. | $66.18 | 2024-2025 | |
| Azurity Pharmaceuticals, INC. | $52.50 | 2023-2024 | Triptodur, Triptodur |
| Abbott Laboratories | $43.29 | 2023 | Freestyle Libre 3 |
| Ultragenyx Pharmaceutical INC. | $36.76 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $31.77 | 2019 | |
| Medtronic, INC. | $21.89 | 2023 | Minimed 780g |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $20.37 | 2023 | Gvoke Hypopen |
| Ibsa Pharma INC. | $16.98 | 2019 | |
| Alexion Pharmaceuticals, INC. | $16.09 | 2024 | |
| Sequel Med Tech, LLC | $16.04 | 2025 | Twiist |
| Insulet Corporation | $15.15 | 2019 | |
| Endo USA, INC. | $13.34 | 2024 | Supprelin |
| Endo Pharmaceuticals INC. | $13.05 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajani Prabhakaran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.